G01N 2333/522
Alpha-chemokines
Official title: Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
G01N2333/522 (Alpha-chemokines) appears on 50 US grants and 133 published applications in this corpus.
Search patents in G01N- Granted patents
- 50
- Published applications
- 133
- Assignees
- 86
- Inventors
- 275
- Latest grant
- 31 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 1 | 1 |
| 2007 | 0 | 1 |
| 2008 | 0 | 2 |
| 2009 | 2 | 2 |
| 2010 | 0 | 1 |
| 2011 | 1 | 5 |
| 2012 | 0 | 3 |
| 2013 | 0 | 4 |
| 2014 | 1 | 7 |
| 2015 | 3 | 12 |
| 2016 | 7 | 13 |
| 2017 | 3 | 11 |
| 2018 | 4 | 8 |
| 2019 | 6 | 7 |
| 2020 | 3 | 5 |
| 2021 | 2 | 5 |
| 2022 | 7 | 13 |
| 2023 | 3 | 8 |
| 2024 | 5 | 6 |
| 2025 | 1 | 9 |
| 2026 | 1 | 9 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for diagnosis and prognosis of renal injury and renal failure31 Mar 2026US 12,590,975 B2Biomerieux
- Atomic description of immune complex that causes heparin-induced thrombocytopenia22 Apr 2025US 12,282,028 B2The Trustees of the University of Pennsylvania
- Biomarkers for assessing risk of transitioning to systemic lupus erythematosus classification and disease pathogenesis12 Nov 2024US 12,140,592 B2Oklahoma Medical Research Foundation
- Method for treating cancer based on expression levels of translationally controlled tumor protein (TCTP)8 Oct 2024US 12,111,318 B2Korea University Research and Business Foundation
- Gene expression markers and treatment of multiple sclerosis24 Sep 2024US 12,098,426 B2Genentech, Inc.
- Biomarkers for predicting cancer treatment efficacy10 Sep 2026US 2026/0266828 A1Arcus Biosciences, Inc.
- Chronic graft-versus-host disease (cgvhd) diagnostic and risk biomarker panels, methods and uses thereof13 Aug 2026US 2026/0235582 A1
- Methods of predicting and treating immunotherapy adverse events based on immune cell populations16 Jul 2026US 2026/0202406 A1Board of Regents, The University of Texas System
- Systemic biomarkers for the dynamic assessment of tumor burden and treatment efficacy in high grade gliomas2 Jul 2026US 2026/0188489 A1Mary Hitchcock Memorial Hospital, for itself and on behalf of Dartmouth-Hitchcock Clinic
- Compositions and methods for the treatment of hemorrhagic shock18 Jun 2026US 2026/0166121 A1Children's Hospital Medical Center
Most cited
By later US patents
- Systems and methods for characterizing kidney diseases29US 7,138,230 B2Renovar Incorporated · 2006
- Methods of using tumor infiltrating lymphocytes in double-refractory melanoma26US 11,433,097 B2Iovance Biotherapeutics, Inc. · 2022
- Methods of using tumor infiltrating lymphocytes in double-refractory melanoma24US 11,819,517 B2Iovance Biotherapeutics, Inc. · 2023
- Signatures and determinants for diagnosing infections and methods of use thereof19US 10,209,260 B2MeMed Diagnostics Ltd. · 2019
- Methods for determining the concentration of an analyte in solution18US 9,809,838 B2Trustees of Tufts College · 2017